Cart
sales@molnova.com
Isorhamnetin 3-glucoside-7-rhamnoside
CAS No. 17331-71-4
Isorhamnetin 3-glucoside-7-rhamnoside( —— )
Catalog No. M31401 CAS No. 17331-71-4
An anti-oxidative composition containing isorhamnetin-3-glucoside-7-rhamnoside (IGR)isolated from Hippophae rhamnoides L. is provided to ensure antioxidative, antibacterial, and anti-cancer effect.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 574 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
Biological Information
-
Product NameIsorhamnetin 3-glucoside-7-rhamnoside
-
NoteResearch use only, not for human use.
-
Brief DescriptionAn anti-oxidative composition containing isorhamnetin-3-glucoside-7-rhamnoside (IGR)isolated from Hippophae rhamnoides L. is provided to ensure antioxidative, antibacterial, and anti-cancer effect.
-
DescriptionAn anti-oxidative composition containing isorhamnetin-3-glucoside-7-rhamnoside (IGR)isolated from Hippophae rhamnoides L. is provided to ensure antioxidative, antibacterial, and anti-cancer effect.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number17331-71-4
-
Formula Weight624.54
-
Molecular FormulaC28H32O16
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
OVA Peptide (257-264...
OVA Peptide (257-264) TFA is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide from ovalbumin presented by the class I MHC molecule, H-2Kb.
-
Nesiritide
Nesiritide is the recombinant form of the 32 amino acid human B-type natriuretic peptide, which is normally produced by the ventricular myocardium. It is an agonist of natriuretic peptide receptors (NPRs), with Kd values of 7.3 and 13 pM for NPR-A and NPR-C, respectively.
-
Irigenin
Irigenin has antifungal activity.
